Retatrutide TRIUMPH-4 Results: 28.7% Weight Loss Across a Diverse Trial Population
TRIUMPH-4 delivered 28.7% mean weight loss — 71.2 lbs over 68 weeks at 12 mg — with consistent efficacy across demographic subgroups. Full breakdown of the data.
The Headline Numbers
TRIUMPH-4 is the retatrutide Phase 3 trial that reset the pharmacotherapy ceiling: mean weight loss of 28.7% — 71.2 lbs from a 248.5 lb baseline — over 68 weeks at the 12 mg weekly dose. That is the highest average weight loss ever recorded in an obesity drug trial, exceeding tirzepatide's 22.5% (SURMOUNT-1) and semaglutide's ~15% (STEP-1) at comparable endpoints.
The dose ladder matters for reading the data: participants titrated 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg in roughly 4-week steps. Efficacy tracked the ladder — lower doses delivered proportionally less, and the 12 mg arm carried both the best results and the most side-effect weeks during escalation.
Why the Diverse Population Design Matters
Earlier incretin trials were criticized for under-representing the populations most affected by obesity. TRIUMPH-4 enrolled deliberately broad demographics — across age bands, sex, race and ethnicity subgroups — and the sub-analyses reported the headline finding held with remarkable consistency: no subgroup lost dramatically less than the mean.
That consistency has practical weight. If you're a 58-year-old woman or a 32-year-old man reading the 28.7% figure, the trial data says the drug's mechanism — GLP-1 appetite suppression, GIP insulin sensitization, glucagon-driven energy expenditure — works across that range. Individual response still varies (trial means hide distributions), but subgroup efficacy gaps that plagued older therapies were not present at meaningful scale.
The diverse-population design also strengthens regulatory expectations: consistent subgroup data is exactly what FDA reviewers look for, and it keeps retatrutide's approval timeline on the optimistic end of projections.
Safety, Access, and What the Data Means for You
TRIUMPH-4's safety profile matched the incretin class: transient GI effects (nausea, vomiting, diarrhea) clustered in titration weeks, plus glucagon-mediated resting heart rate elevation of a few BPM that tapered with time. No new safety signals emerged at the highest dose.
The access reality in 2026: retatrutide is NOT FDA-approved, and FDA has stated it cannot be lawfully compounded under 503A/503B. Trial enrollment is the only sanctioned access channel. Gray-market 'retatrutide' circulates with zero purity verification — our vendor database tracks which suppliers provide real third-party COAs.
For those evaluating or planning protocols, our retatrutide dosage calculator converts every step of the 0.5→12 mg ladder into exact reconstitution volumes and syringe math, and the full dosing guide covers weekly scheduling, stall troubleshooting, and side-effect management with the training and protein anchors that protect lean mass.
📊 Dosage Calculator & Protocol Chart
Use our free Retatrutide dosage calculator to plan your protocol:
👉 Retatrutide Dosage Calculator — Calculate exact dosing, reconstitution ratios, and injection volumes.
👉 Full Dosing Guide & Protocol Chart — Complete protocol with weekly titration schedule, side effect management, and cycle recommendations.
Important Disclaimer
This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.
Keywords: retatrutide TRIUMPH-4, 28.7 percent weight loss, retatrutide phase 3 results, retatrutide diverse population trial, retatrutide 71 lbs weight loss
Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content